Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| PLC SYSTEMS INC | 7,310,231 | reported | 14 May 2015 | tx 2+675,675 |
| Cabaletta Bio, Inc. | 2,614,575 | reported | 12 Jan 2021 | tx 4−387,000 |
| Crinetics Pharmaceuticals, Inc. | 2,267,797 | reported | 21 Jun 2019 | tx 14+3,499,278−11,539,117 |
| IMPEL NEUROPHARMA INC | 1,359,799.28 | reported | 22 Apr 2021 | tx 1+1,359,799.28 |
| Q32 Bio Inc. | 221,435 | reported | 16 May 2019 | tx 4−630,575 |
| CUBIST PHARMACEUTICALS INC | 191,448 | reported | 30 Sept 2004 | tx 41+97,378−141,545 |
| Skye Bioscience, Inc. | 57,493 | reported | 22 Aug 2025 | tx 4−231,405 |
| Cidara Therapeutics, Inc. | 11,000 | reported | 13 Jun 2018 | tx 8+1,849,662−1,809,662 |
| Achaogen Inc | 10,000 | reported | 11 Mar 2014 | tx 1+10,000 |
| COMBINATORX, INC | 9,000 | reported | 05 Jun 2015 | tx 3+409,000 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 21 Aug 2025 | SALE | Skye Bioscience, Inc. | 58,642 | 3.57 USD | |
| 22 Aug 2025 | SALE | Skye Bioscience, Inc. | 6,470 | 3.42 USD | |
| 22 Aug 2025 | SALE | Skye Bioscience, Inc. | 163,979 | 3.42 USD | |
| 21 Aug 2025 | SALE | Skye Bioscience, Inc. | 2,314 | 3.57 USD | |
| 22 Apr 2021 | OTHER | IMPEL NEUROPHARMA INC | 1,359,799.28 | 0.00 USD | deriv |
| 08 Jan 2021 | SALE | Cabaletta Bio, Inc. | 264,589 | 13.00 USD | |
| 08 Jan 2021 | SALE | Cabaletta Bio, Inc. | 37,411 | 13.00 USD | |
| 12 Jan 2021 | SALE | Cabaletta Bio, Inc. | 10,530 | 13.00 USD | |
| 12 Jan 2021 | SALE | Cabaletta Bio, Inc. | 74,470 | 13.00 USD | |
| 30 Jun 2020 | GRANT_AWARD | Aprea Therapeutics, Inc. | 5,600 | 0.00 USD | deriv |
| 16 Jun 2020 | SALE | Aprea Therapeutics, Inc. | 115,357 | 33.30 USD | |
| 16 Jun 2020 | SALE | Aprea Therapeutics, Inc. | 4,807 | 33.30 USD | |
| 11 Jun 2020 | SALE | Aprea Therapeutics, Inc. | 235,200 | 28.75 USD | |
| 11 Jun 2020 | SALE | Aprea Therapeutics, Inc. | 9,800 | 28.75 USD | |
| 19 May 2020 | SALE | Aprea Therapeutics, Inc. | 10,200 | 35.15 USD | |
| 19 May 2020 | SALE | Aprea Therapeutics, Inc. | 244,800 | 35.15 USD | |
| 07 Oct 2019 | CONVERSION | Aprea Therapeutics, Inc. | 492,475 | — | |
| 07 Oct 2019 | CONVERSION | Aprea Therapeutics, Inc. | 20,519 | — | |
| 07 Oct 2019 | CONVERSION | Aprea Therapeutics, Inc. | 1,913,910 | — | |
| 07 Oct 2019 | CONVERSION | Aprea Therapeutics, Inc. | 79,746 | — | |
| 07 Oct 2019 | CONVERSION | Aprea Therapeutics, Inc. | 20,519 | — | deriv |
| 07 Oct 2019 | CONVERSION | Aprea Therapeutics, Inc. | 1,913,910 | — | deriv |
| 07 Oct 2019 | CONVERSION | Aprea Therapeutics, Inc. | 79,746 | — | deriv |
| 07 Oct 2019 | CONVERSION | Aprea Therapeutics, Inc. | 492,475 | — | deriv |
| 21 Jun 2019 | SALE | Crinetics Pharmaceuticals, Inc. | 10,000 | 22.20 USD |
2 purchases reported after at least 12 months of silence — most recent on 20 Jul 2018.